Trials / Completed
CompletedNCT01727232
Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 107 (actual)
- Sponsor
- Henri Mondor University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .
Detailed description
Every adult (age ≥ 18 years) seen in one of the 3 participating centre (dijon, Marseille, Mondor) over a 7-year period (2005-2012) with a definite diagnosis of primary ITP according to the American Society Hematology guidelines who received RTX regardless the regimen could be included.
Conditions
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2012-06-01
- Completion
- 2012-10-01
- First posted
- 2012-11-15
- Last updated
- 2012-11-15
Source: ClinicalTrials.gov record NCT01727232. Inclusion in this directory is not an endorsement.